Lower urinary tract symptoms/benign prostatic hyperplasia: Minimizing morbidity caused by treatment

Urology

Volumn 62, Issue 3 SUPPL. 1, 2003, Pages 24-33

  Schulman, Claude C ^a  

^a ERASME HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; FINASTERIDE; TAMSULOSIN; TERAZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; STEROID 5ALPHA REDUCTASE; SULFONAMIDE;

ASTHENIA; BLOOD PRESSURE REGULATION; CARDIOVASCULAR SYMPTOM; CLINICAL TRIAL; DIZZINESS; DOSE RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EJACULATION DISORDER; FAINTNESS; HEADACHE; HUMAN; IMPOTENCE; LIBIDO DISORDER; MONOTHERAPY; MORBIDITY; NAUSEA; ORTHOSTATIC HYPOTENSION; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RETROGRADE EJACULATION; REVIEW; SOMNOLENCE; SYNCOPE; AGED; BLOOD PRESSURE; DRUG ANTAGONISM; DRUG COMBINATION; DRUG EFFECT; EJACULATION; MALE; MICTURITION DISORDER; PHYTOTHERAPY;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; BLOOD PRESSURE; DRUG THERAPY, COMBINATION; EJACULATION; HUMANS; IMPOTENCE; MALE; PHYTOTHERAPY; PROSTATIC HYPERPLASIA; SULFONAMIDES; TESTOSTERONE 5-ALPHA-REDUCTASE; URINATION DISORDERS;

EID: 0042885514     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/S0090-4295(03)00471-0     Document Type: Article

References (45)

1. Djavan B: Lower urinary tract symptoms/benign prostatic hyperplasia: fast control of the patient's quality of life. Urology 62(suppl 3A): 6-14, 2003.
2. O'Leary MP: Lower urinary tract symptoms/benign prostatic hyperplasia: maintaining symptom control and reducing complications. Urology 62(suppl 3A): 15-23, 2003.
3. Speakman MJ: Initial choices and final outcomes in lower urinary tract symptoms. Eur Urol 40(suppl 4): 21-30, 2001.
4. Barry M, and Roehrborn C: Benign prostatic hyperplasia. Clinical Evidence 4: 453-461, 2000.
5. Chapple CR: Introduction and concluding remarks. Eur Urol 36(suppl 3): 1-6, 1999.
6. Roehrbom CG: The newly established guidelines for the diagnosis and management of benign prostatic hyperplasia. Curr Opin Urol 5: 30-34, 1995.
7. Debruyne FMJ, Jardin A, Colloi D, et al: Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. Eur Urol 34: 169-175, 1998.
8. Nickel JC, Fradet Y, Boake RC, et al: Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomised controlled trial (the PROSPECT study). CMAJ 155: 1251-1259, 1996.
9. Lepor H, Williford WO, Barry MJ, et al: The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med 335: 533-539, 1996.
10. McConnell JD: The long-term effects of medical therapy on the progression of BPH: results from the MTOPS trial. J Urol 167(suppl 4): 265, 2002. Abstract 1042.
11. Djavan B, and Marberger M: A meta-analysis on the efficacy and tolerability of α1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 36: 1-13, 1999.
12. Zlotta AR, and Schulman CC: BPH and sexuality. Eur Urol 36(suppl 1): 107-112, 1999.
13. Hatano A, Takahashi H, Tamaki M, et al: Pharmacological evidence of distinct α1-adrenoceptor subtypes mediating the contraction of human prostatic urethra and peripheral artery. Br J Pharmacol 113: 723-728, 1994.
14. Rudner XL, Berkowitz DE, Booth JV, et al: Subtype specific regulation of human vascular alpha(1)-adrenergic receptors by vessel bed and age. Circulation 100: 2336-2343, 1999.
15. 1-adrenoceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy. Eur J Pharmacol 288: 201-207, 1995.
16. Buzelin JM, Fonteyne E, Kontturi M, et al: Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). Br J Urol 80: 597-605, 1997.
17. De Mey C, and Terpstra I: Orthostatic effects of alfuzosin twice daily vs. tamsulosin once daily in the morning. J Urol 163(suppl): 220, 2000 Abstract 978.
18. De Mey C, Michel MC, McEwen J, et al: A double-blind comparison of terazosin and tamsulosin on their differential effects on ambulatory blood pressure and nocturnal orthostatic stress testing. Eur Urol 33: 481-488, 1998.
19. Lowe F, Narayan P, and Djavan B: Prospective, randomised multicentre trial to evaluate the rapidity of onset and side effect profile of tamsulosin (TAM) vs terazosin (TER) in men with benign prostatic hyperplasia (BPH). Eur Urol Suppl 1: 108, 2002. Abstract 421.
20. Roehrborn CG, and Siegel RL: Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. Urology 48: 406-415, 1996.
21. Roehrborn CG, Oesterling JE, Auerbach S, et al: The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. Urology 47: 159-168, 1996.
22. Debruyne F, Koch G, Boyle P, et al: Comparison of a phytotherapeutic agent (permixon) with an α-blocker (tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomised international study. Eur Urol 41: 497-507, 2002.
23. Walden PD, Durkin MM, Lepor H, et al: Localization of mRNA and receptor subtype binding sites for the alpha 1A-adrenoceptor subtype in the rat, monkey and human urinary bladder and prostate. J Urol 157: 1032-1038, 1997.
24. Furukawa K, Rosario DJ, Smith DJ, et al: Alpha 1A-adrenoceptor-mediated contractile responses of the human vas deferens. Br J Pharmacol 116: 1605-1610, 1995.
25. Moriyama N, Nasu K, Takeuchi T, et al: Quantification and distribution of α1-adrenoceptor subtype mRNAs in human vas deferens: comparison with those of epididymal and pelvic portions. Br J Pharmacol 122: 1009-1014, 1997.
26. Höfner K, Claes H, De Reijke TM, et al: Tamsulosin 0.4 mg once daily: effect on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 36: 335-341, 1999.
27. Lepor H: Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Urology 51: 892-900, 1998.
28. Narayan P, Tewari A, for the United States 93-01 Study Group: A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. J Urol 160: 1701-1706, 1998.
29. Schulman CC, Lock TMTW, Buzelin JM, et al: Long-term use of tamsulosin to treat lower urinary tract symptoms/benign prostatic hyperplasia. J Urol 166: 1358-1363, 2001.
30. Mann RD, Biswas P, Freemantle S, et al: The pharmacovigilance of tamsulosin: event data on 12 484 patients. BJU Int 85: 446-450, 2000.
31. Debruyne F, and Narayan P: Tamsulosin improves sexual function with minimal abnormal ejaculation in patients treated for lower urinary tract symptoms suggestive of benign prostatic hyperplasia. BJU Int 90(suppl 2): 12, 2002. Abstract P-1.2.01.
32. 1A-adrenoceptor antagonist: a meta-analysis of two randomised, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). Eur Urol 29: 155-167, 1996.
33. 1A-adrenoceptor antagonists in benign prostatic hyperplasia: studies on tamsulosin in a fixed dose and terazosin in increasing doses. Br J Urol 80: 606-611, 1997.
34. Na YJ, Guo YL, and Gu FL: Clinical comparison of selective and non-selective alpha1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. J Med 29: 289-303, 1998.
35. Schou J, Holm NR, and Meyhoff HH: Sexual function in patients with symptomatic benign prostatic hyperplasia. Scand J Urol Nephrol Suppl 179: 119-122, 1996.
36. Scarpa RM: Lower urinary tract symptoms: what are the implications for the patients? Eur Urol 40(suppl 4): 12-20, 2001.
37. Emberton M, Neal DE, Black N, et al: The effect of prostatectomy on symptom severity and quality of life. Br J Urol 77: 233-247, 1996.
38. Frankel SJ, Donovan JL, Peters TI, et al: Sexual dysfunction in men with lower urinary tract symptoms. J Clin Epidemiol 51: 677-685, 1998.
39. Robertson C, Boyle P, Mazzetta C, et al: The impact of lower urinary tract symptoms on erectile dysfunction and sexual drive: the Urepik study. J Urol 16(suppl 4): 268, 2002. Abstract 1055.
40. MacFarlane GJ, Botto H, Sagnier PP, et al: The relationship between sexual life and urinary condition in the French community. J Clin Epidemiol 49: 1171-1176, 1996.
41. Calais da Silva F, Marquis P, Deschaseaux P, et al: Relative importance of sexuality and quality of life in patients with prostatic symptoms: results from an international study. Eur Urol 31: 272-280, 1997.
42. Emberton M, Vallancien G, Van Moortselaar J, et al: Sexual dysfunction in patients with lower urinary tract symptoms. J Urol 167(suppl 4): 271, 2002. Abstract 1066.
43. Palacio A, Batista JE, Torrubia R, et al: Tamsulosin: effect on sexual function in almost 3000 patients with LUTS managed in real life practice in Spain. Br J Urol 86(suppl 3): 32-33, 2000. Abstract P1.4.20.
44. Lukacs B, Leplege A, Thibault P, et al: Prospective study of men with clinical benign prostatic hyperplasia treated with alfuzosin by general practitioners: 1-year results. Urology 48: 731-740, 1996.
45. Kirby R, Roehrborn C, Boyle P, et al: Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology 61: 119-126, 2003.